Introduction {#s1}
============

Pallial interneurons (INs) consist of cortical interneurons (CINs) and hippocampal interneurons (HINs). IN pathologies are hypothesized to underlie symptoms of neurological and neuropsychiatric disorders such as autism spectrum disorder (ASD), epilepsy and schizophrenia. One possible explanation is that IN pathology leads to disrupted circuit inhibition, resulting in circuit hyperexcitability and less efficient information processing ([@bib25]; [@bib45]; [@bib50]; [@bib68]). Thus, understanding the genetic control of CIN and HIN development and function can have important clinical ramifications.

CINs are generated in three subpallial progenitor domains: the medial and caudal ganglionic eminences (MGE and CGE), and the preotic area (POA) ([@bib18]; [@bib25]). MGE and POA-derived CINs express parvalbumin (PV) or somatostatin (SST), while CGE-derived CINs express either vasoactive intestinal peptide (VIP), cholecystokinin (CCK) or reelin \[but lack SST\]. HINs are generated by the same general progenitor pools and share similar molecular properties with CINs. However, so far there are no clear single markers that are known to define developing or mature HINs from CINs ([@bib42]).

We have recently demonstrated that two *Maf* TFs, *Maf* (*c-Maf*) and *Mafb*, function together in the MGE to control the timing and quantity of SST^+^ CINs that are generated ([@bib40]), schematically summarized in [Schemes 1](#C1){ref-type="fig"}--[3](#C3){ref-type="fig"}. Loss of *Mafb* and *Maf* in the *Nkx2.1-Cre* lineage (*Maf* cDKO) leads to the overproduction of SST^+^ CINs at the expense of PV^+^ CINs. *Maf* cDKOs also have changes in the quantity and distribution of the total *Nkx2.1-cre* lineage INs: reduced CINs (\~30%) and increased HINs (\~2 fold) at P0, and a progressive loss of INs that plateaued by adulthood at \~70% reduction ([Schemes 1](#C1){ref-type="fig"} and [2](#C2){ref-type="fig"}). Loss of *Maf* and *Mafb* also alters postnatal CIN properties, including process morphogenesis, synaptogenesis, intrinsic electrophysiology and circuit excitability ([@bib40]; [Schemes 2](#C2){ref-type="fig"} and [3](#C3){ref-type="fig"}). However, the gene targets of *Mafb* and *Maf* that underlie these phenotypes remain to be elucidated.

![Schema depicting the prenatal roles of *Maf* and *Mafb.*\
In [@bib40], we described that the expression of *Maf* and *Mafb* starts in the MGE SVZ. Deletion of *Maf* and *Mafb* using the *Nkx2.1-Cre* (*Maf* cDKO) leads to increased neurogenesis in the MGE SVZ and overproduction of somatostatin (SST) interneurons. In this paper, we aim to identify the downstream gene targets of *Maf* and *Mafb* that are involved in this process. SVZ: subventricular zone. MZ: mantle zone.](elife-54903-fig10){#C1}

![Schema depicting the postnatal roles of *Maf* and *Mafb*.\
In [@bib40], we discovered that the adult *Maf* cDKO mice have drastic reduction of MGE-derived cortical interneurons (CINs) and a preferential loss of parvalbumin (PV) INs. In this paper, we aim to identify potential downstream gene targets of *Maf* and *Mafb* that are involved in PV CIN fate specification and differentiation. In this paper, we also provide data that suggest adult *Maf* cDKO animals have spontaneous epileptic activity in vivo.](elife-54903-fig11){#C2}

![Loss of *Maf* and *Mafb* leads to MGE-derived IN morphogenesis defect.\
In [@bib40], we showed that cultured neonatal *Maf* cDKO interneurons have neurite outgrowth defect compared to the WT counterparts. In this paper, we aim to identify gene targets of *Maf* and *Mafb* that are involved in CIN morphological maturation.](elife-54903-fig12){#C3}

Herein, we uncovered a set of *Maf* and *Mafb* regulated genes by performing single cell RNA-sequencing (scRNA-seq) of neonatal CINs and HINs from wild type (WT) and cDKO. These include *Sst, neuropilin1* (*Nrp1*), and several genes that are implicated in neuropsychiatric disorders, including myocyte enhancer factor 2C (*Mef2c*) (ASD, [@bib61]), synaptosome associated protein 25 (*Snap25*) (schizophrenia, [@bib22]), and C-X-C motif chemokine receptor 4 (*Cxcr4*) (22q11.2 deletion syndrome; [@bib30]). We provide evidence that *Maf* and *Mafb* promote *Mef2c* expression, which in turn promotes PV^+^ IN differentiation. We show that *Maf* and *Mafb* also have postnatal functions in CIN morphological maturation. Furthermore, we identified a secreted peptide encoding gene, prepronociceptin (*Pnoc*), as an immature HIN marker. Finally, we provide evidence that *Maf* and *Mafb* control the balance between CIN and HIN production.

Results {#s2}
=======

Single cell transcriptomic profiling of P0 WT and *Maf* cDKO {#s2-1}
------------------------------------------------------------

Deletion of both *Maf* (*c-Maf*) and *Mafb* using *Nkx2.1-Cre* (*Maf* cDKO) led to an overproduction of *Sst^+^* CINs, a drastic loss of total MGE-derived CINs and abnormal electrophysiological properties ([@bib40]). Furthermore, adult *Maf* cDKOs have spontaneous non-motor epileptic activity, likely associated with the interneuronopathy ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). The underlying gene targets of *Maf* and *Mafb* that may regulate these processes are explored below.

To identify dysregulated genetic targets in cDKO immature INs, we used scRNA-seq from P0 WT and cDKO neocortices ([Figure 1A--D](#fig1){ref-type="fig"}). We pooled the WT and cDKO datasets to perform unsupervised data analysis using Seurat pipeline ([@bib7]; [@bib17]). We identified 24 different clusters, including excitatory neurons, neural progenitors, microglia as well as MGE and CGE-derived INs, which were visualized by uniform manifold approximation and projection (UMAP) ([Figure 1B and C](#fig1){ref-type="fig"}; [@bib6]). We assigned the cell identities to each cluster based on the expression of established marker genes ([Figure 1---figure supplements 2](#fig1s2){ref-type="fig"} and [3](#fig1s3){ref-type="fig"}, [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}; [@bib29]; [@bib38]; [@bib60]). MGE-derived INs were in cluster 1, based on marker gene co-expression, including *LIM homeobox 6* (*Lhx6*), *Maf*, *Mafb* and *neurexophilin 1* (*Nxph1*) ([Figure 1E](#fig1){ref-type="fig"}, [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}, [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). We performed fluorescent in situ hybridization (FISH) to confirm the specificity of *Nxph1* expression within the *Nkx2.1*-lineage by co-labeling *Nxph1* and *Nkx2.1-Cre* driven *tdTomato* ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}).

![Single cell transcriptomic analysis of P0 WT and *Maf* cDKO neocortex.\
(**A**) Experimental design for 10X genomics analysis of the P0 WT and *Maf* cDKO neocortex. Neocortical tissues were dissociated for single cell gel bead-in-emulsion (GEMs) particle preparation, followed by cDNA library preparation, sequencing and data analysis. (**B**) UMAP plot of WT and cDKO cells, color coded with cluster identities (see [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). (**C**) UMAP plot of WT and cDKO cells, color coded with genotypes; cluster one are MGE INs. Note the genotype separation of the cells in cluster 1 (left bottom), but not other clusters, suggesting the lack of non-cell autonomous effects of the *cDKO*. (**D**) Heatmap showing cluster identities with corresponding marker genes. (**E**) Heatmap of cluster 1 cells from WT and cDKO showing average expression of selected MGE IN markers and pan-IN markers. Note the nearly full depletion of *Mafb* and *Maf* and increased expression of *Sst*, and the decreased expression of *Mef2c*, while other MGE-derived IN markers such as *Dlx1/2/5*, *Gad2* and *Lhx6* were not changed. This suggests that the deletion of *Maf*s in the MGE-lineage does not lead to a gross change in MGE-derived IN fate. (**F--G**) Enlarged feature plots showing the expression of *Mef2c* (**F**) and *Sst* (**G**) from WT and cDKO from cluster 1. (**H--I**) FISH in *Sst* together with EdU labeling showing the amount of E15.5 born MGE-derived CINs that became *Sst*^+^ in WTs and cDKOs. Arrows point to the cells that are EdU^+^;*Sst*^+^. (**J**) Quantification of *Sst*^+^ CINs at P2 WT and cDKO neocortex. (**K**) Quantification of EdU^+^;*Sst*^+^ CINs at P2 WT and cDKO neocortex. (**L--M**) Immunofluorescent staining of MEF2C colocalized with *Nkx2.1-cre*-driven tdTomato reporter. P2 *Maf* cDKOs have decreased MEF2C expression (**M**) compared to WTs (**L**). (**N**) Quantification of the proportion of tdTomato^+^ CINs that were MEF2C^+^ by bins. N = 3--4 animals per group and multiple brain sections were used for quantification. Scale bar in (**I**) = 100 um and in (**M**) = 50 um. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001.\
Figure 1---source data 1.Cluster marker gene list Here we provide a list of genes that were used to define each cluster's identity.](elife-54903-fig1){#fig1}

There were no obvious transcriptomic changes in neural progenitors, excitatory neurons, oligodendrocytes, microglia and the CGE-derived IN population between WT and cDKO ([Figure 1B and C](#fig1){ref-type="fig"}). This suggests no gross non-cell autonomous effects exerted by loss of *Maf* and *Mafb* in the *Nkx2.1-Cre*-lineage. However, the MGE-derived IN population (cluster 1) showed clear differences between WT and cDKO ([Figure 1C](#fig1){ref-type="fig"}). We performed differential gene expression (DEX) analysis in this MGE-derived IN cluster, and identified 81 differentially expressed (DE) genes, with 47 upregulated (including *Sst*, *Nrp1*, *Pnoc* and *Neuropeptide Y*) and 34 down-regulated (including *Maf*, *Mafb*, *Neurexophilin2*, *Mef2c*, *Cxcr4* and *Snap25*) in the *Maf* cDKO ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}). We performed either immunohistochemistry or FISH to confirm the pattern of gene expression changes between control and cDKOs, including *Mef2c*, *Sst*, *Neurexophilin2* (*Nxph2*), *Cxcr4*, *Neuropeptide Y* (*Npy*) and *Nrp1* ([Figure 1F--N](#fig1){ref-type="fig"}, [Figure 1---figure supplements 4](#fig1s4){ref-type="fig"}--[7](#fig1s7){ref-type="fig"}). Gene ontology analysis, based upon cellular components, showed that most dysregulated genes are involved in synapse formation, neurite projection and neuronal maturation. Thus, the transcriptomic analysis provides molecular insights into the *Maf* cDKOs cellular phenotypes ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}; [@bib17]; [@bib40]).

Loss of *Maf* and *Mafb* leads to decreased MEF2C expression and increased *Sst^+^* CINs {#s2-2}
----------------------------------------------------------------------------------------

Based on DEX analysis, *Mef2c* was the third most down-regulated gene, while *Sst* was the most upregulated gene ([Figure 1F--G](#fig1){ref-type="fig"}, S7). To validate the *Mef2c* result, we used immunofluorescence labeling; MEF2C expression was reduced in the tdTomato^+^ CINs across all cortical layers in the P2 cDKOs ([Figure 1F and L--N](#fig1){ref-type="fig"}) (Bin 3, 4, 7: p\<0.05; Bin 5, 6: p\<0.01; Density: p\<0.01; Welch's t test) (tdTomato fluorophore was generated by crossing Ai14 Rosa26-tdTomato *Cre* reporter *with Nkx2.1-Cre;* we will refer to the *Cre* reporter allele as RosaT and the expressed reporter as tdTomato throughout the paper)([@bib32]). To validate the *Sst* result, we used FISH; we found both increased *Sst* ISH signal and increased numbers of *Sst*^+^ CINs at P2 in cDKOs as before ([Figure 1G and H--J](#fig1){ref-type="fig"}) (*Sst* density: p=0.0001, Welch's t test) ([@bib40]).

Since the *Maf* cDKO generated excessive *Sst*^+^ CINs at E13.5 ([@bib40]), we also asked if excessive *Sst^+^* CINs were generated at later developmental time points. Thus, we injected EdU in E15.5 pregnant mice and assessed the neocortical *Sst*^+^ INs at P2. There was a \> 3 fold increase in *Sst* and EdU double labeled CINs in P2 cDKO neocortices ([Figure 1K](#fig1){ref-type="fig"}) (*Sst*-EdU density: p\<0.0001; Welch's t test). Thus, *Maf* cDKOs overproduce *Sst^+^* CINs across development.

*Maf* and *Mafb* drive *Mef2c* expression to promote PV^+^ CIN generation {#s2-3}
-------------------------------------------------------------------------

Prenatal loss of *Mef2c* reduces the number of PV^+^ CINs ([@bib36]). Given our finding that *Mef2c* expression is reduced in *Maf* cDKOs ([Figure 1](#fig1){ref-type="fig"}), it suggests that *Maf* and *Mafb* are genetically upstream of *Mef2c*. We thus hypothesized that deficits in *Mef2c* potentially underlie the mechanisms causal to the PV^+^ CIN loss in the *Maf* cDKO (this report; [@bib40]). We tested this by increasing MEF2C levels in *Maf* cDKO MGE cells.

To this end, we used an MGE transplantation rescue assay ([@bib62]; [@bib63]), which previously showed that the *Maf* cDKO had reduced PV^+^ CINs, recapitulating the cDKO in vivo phenotype ([@bib40]). E13.5 MGEs (RosaT*^+^* or *Maf^f/f^; Mafb^f/f^;* RosaT*^+^*) were dissociated and then transfected with a *Cre*-expressing plasmid to generate tdTomato^+^ WT or cDKO MGE-lineage cells. In parallel, some of the MGE cells were co-transfected with plasmids expressing *Cre* and *Mef2c.* The transfected cells were transplanted into WT P1 neocortices and were assessed 30 days later via SST and PV immunofluorescence ([Figure 2A and C--K](#fig2){ref-type="fig"}).

![*Mef2c* rescues the deficit of PV CIN production in cDKOs.\
(**A**) Schema showing the MGE transplantation assay. RosaT^+^ or *Maf^f/f^;Mafb^f/f^;*RosaT^+^ MGE progenitors were dissected at E13.5, followed by transfection of *Cre* or *Cre + Mef2c* (expression vectors) to generate cDKO or cDKO + *Mef2c* MGE cells. We transplanted these cells into P1 WT neocortex and let them mature for 30 days before investigating CIN subtype markers. (**B**) Quantification of the proportion of transplanted WT, cDKO or cDKO with transfected *Mef2c* CINs that express either SST or PV. Note that the cDKO group recapitulated the phenotype of preferential loss of PV CINs; transfection with *Mef2c* rescued the production of PV CINs. *Chi*-square test was used for statistical analysis. (**C--K**) Representative singular cell images for group WT, cDKO and cDKO+*Mef2c* that are labeled with tdTomato and PV. Note that cDKO (**F**) has less complex neurite growing pattern compared to the WT (**C**). Also note the rescue of the PV expression in the cDKO+*Mef2c* (**K**) compared with the cDKO (**H**). Scale bar in (**K**) = 25 um. For SST IN comparison: WT-701 cells, cDKO-627 cells, cDKO+*Mef2c*- 304 cells; For PV IN comparison: WT- 670 cells, cDKO-587 cells, cDKO+*Mef2c* −236 cells. These numbers came from 6 WT animals, 4 cDKO animals and 3 cDKO + *Mef2c* animals. Cells analyzed were converted to contingency table to conduct *Chi*-square test. \*\*\*\*p\<0.0001. Error bars represent standard errors of the mean.](elife-54903-fig2){#fig2}

The analysis confirmed the preferential loss of PV^+^ CINs in the cDKOs ([@bib40]; [Figure 2B](#fig2){ref-type="fig"}). Importantly, we found that *Mef2c* transfection rescued this phenotype, and corrected the SST/PV ratio ([Figure 2B and K](#fig2){ref-type="fig"}) (PV population: WT vs. cDKO p\<0.0001; cDKO vs. cDKO+*Mef2c* p\<0.0001; *Chi*-square test). Together, these data suggest that *Maf* and *Mafb* promote *Mef2c* expression, which in turn promotes the PV^+^ IN fate ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}. Model).

Identification of transcriptomic features of candidate immature PV^+^ INs {#s2-4}
-------------------------------------------------------------------------

Studies have strived to identify transcriptional machinery that differentially controls PV vs. SST IN neurogenesis. Our current study has solidified a transcriptional cascade, *Maf/Mafb* → *Mef2c* → PV, that is involved in this process ([Figure 2](#fig2){ref-type="fig"}). However, there are no known early markers that specifically delineate immature PV^+^ INs before PV expression begins ([@bib12]).

We hypothesize that within MGE-derived INs, the *Sst*-negative (*Sst*^-^) group primarily comprises the future PV^+^ INs, in part since *Sst-IRES-Cre* lineage tracing showed that the majority of the SST^+^ INs remain SST^+^ ([@bib40]; [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). We computationally separated WT cluster 1 MGE-derived INs into *Sst^+^* and *Sst^-^* subgroups and evaluated the mean expression of MGE IN markers ([Figure 3A](#fig3){ref-type="fig"}). We identified a group of genes that are enriched in the *Sst*^-^ population, by comparing the IN marker expression between the two groups ([Figure 3](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). From these, we selected six genes, ADP ribosylation factor like GTPase 4D (*Arl4d*), engulfment and cell motility protein 1 (*Elmo1*), insulin like growth factor binding protein 4 (*Igfbp4*), *Mef2c*, *Sp9* and transcription factor 12 (*Tcf12*), with high-to-moderate expression to evaluate their RNA expression.

![Multiplex RNA in situ hybridization validation of proposed immature PV IN markers.\
(**A**) Heatmap of MGE IN marker genes for cluster 1 *Sst^-^* and *Sst^+^* INs. (**B--D''**) Lower magnification fluorescent images of multiplex RNA in situ hybridization for *Mef2c* (**B--B''**), *Sp9* (**C--C''**) and *Igfbp4* (**D--D''**). (**E--G'''**) Higher magnification fluorescent images of multiplex RNA in situ hybridization for *Mef2c* (**E--E'''**), *Sp9* (**F--F'''**) and *Igfbp4* (**G--G'''**). White arrows point to INs that are marker (*Mef2c*, *Sp9* or *Igfbp4*) and *tdTomato* positive but *Sst* negative. Violin plots showing the normalized expression value (Y-axis) of each cell analyzed in each group for *Mef2c* (**H**), *Sp9* (**J**) and *Igfbp4* (**L**). Quantification of the percentage of *tdTomato^+^; Sst^-^* and *tdTomato^+^; Sst^+^* INs in the neocortex and in the hippocampus that are either *Mef2c^+^*(**I**), *Sp9^+^*(**K**) or *Igfbp4^+^*(**M**). Scale bar in (**B**) = 100 um, (**B''**) = 200 um and (**G**) = 25 um. 2 WTs and multiple brain sections per animal were used for quantification. For statistical analysis, multiple independent t-tests without same standard deviation assumption were conducted to compare the expression of each gene in each brain region. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001.](elife-54903-fig3){#fig3}

We used P2 WT tissues which were triple-labeled with *Nkx2.1-Cre*-driven *tdTomato*, *Sst* and an RNA of each of the six genes; the RNAs were detected using RNAscope ([Figure 3B--G'''](#fig3){ref-type="fig"}, [Figure 3---figure supplements 2](#fig3s2){ref-type="fig"} and [3](#fig3s3){ref-type="fig"}). We quantified the proportion of *tdTomato*^+^; *Sst*^+^ or *tdTomato*^+^; *Sst*^-^ INs that were positive for each gene ([Figure 3I, K and M](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Our results suggested that *Mef2c* is a very specific *Sst*^-^ population marker, especially in the hippocampus (Cortex: p\<0.05; Hippocampus: p\<0.0001). Likewise, *Elmo1, Igfbp4*, and *Sp9* appear to be good markers for *Sst*^-^ MGE-derived INs in the hippocampus (*Elmo1*: p\<0.001; *Igfbp4*: p\<0.05; *Tcf12*: p\<0.01; unpaired test). This likely is the first study to identify genes, such as *Mef2c*, that are almost exclusively expressed in *Sst*^-^ MGE-derived immature HINs.

*Maf* and *Mafb* control CIN morphological maturation by regulating *Mef2c* and *Snap25* {#s2-5}
----------------------------------------------------------------------------------------

Reduced expression of *Mef2c* and *Snap25* was shown to impede neurite morphogenesis ([@bib20]; [@bib22]; [@bib61]). Since *Maf* cDKOs have a neurite outgrowth defect in vitro and in vivo ([@bib40], [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), we examined whether the decreased expression of *Mef2c* and *Snap25* in the cDKOs underlies their neurite outgrowth defect ([@bib40]).

To evaluate this, we tested whether transfection of these genes could rescue the *Maf* cDKO neurite phenotype using primary cell cultures of P1 neocortical neurons. Expression vectors encoding G*fp*, *Gfp-tagged Maf*, *Mef2c* or *Snap25* were transfected into *Nkx2.1-Cre*-lineage CINs (tdTomato^+^) the day after cell plating (DIV1). At DIV 14, CIN morphology was assessed ([Figure 4A](#fig4){ref-type="fig"}). As before, cDKO CINs had decreased numbers of neurites; *Gfp* transfection did not alter this phenotype ([Figure 4B, C and G](#fig4){ref-type="fig"}). Second, transfection of cDKO with *Maf, Mef2c* or *Snap25* rescued neurite numbers, and the increased neurite numbers were comparable to WT ([Figure 4B, D--F and H--I](#fig4){ref-type="fig"}). These results provide evidence that reduced *Mef2c* and *Snap25* expression are downstream of *Maf* and *Mafb* in regulating neurite complexity in neonatal CINs.

![*Mef2c* and *Snap25* are required downstream of *Mafb* and *Maf* to promote neurite outgrowth.\
**A**) Schema showing the in vitro culture assay testing *Maf* and *Mafb*'s prenatal function on neurite outgrowth. P0 WT and cDKO neocortical tissues were dissociated (INs were labeled with *Nkx2.1-cre*-driven tdTomato) and diluted 5-fold with reporter negative dissociated P0 WT neocortical tissues before plating on culture slides. (**B--C**) Representative traces of cultured WT and cDKO INs. (**D--F**) Representative traces of cultured cDKO INs transfected with *Maf*, *Mef2c* or *Snap25*-expressing plasmids; each showed a rescue phenotype. (**G--I**) Sholl analysis showing the neurite complexity and the rescue effects of *Maf* (**G**), *Mef2c* (**H**) and *Snap25* (**I**). (**J**) Schema showing the in vitro culture assay testing *Maf* and *Mafb*'s postnatal function on neurite outgrowth. (**K--O**) Representative traces of cultured INs using *Maf^f/f^;Mafb^f/f^;* RosaT^+^ P0 neocortices to look at the effect of postnatal deletion of *Maf* and *Mafb* on neurite outgrowth and if *Maf*, *Mef2c* and *Snap25* expression showed rescue effects. Thus, postnatal loss of *Maf* and *Mafb* (cDKO^POST^) leads to defects in neurite outgrowth (**K--L**). (**P--R**) Sholl analysis showing the neurite complexity and the rescue effects of *Maf* (**P**), *Mef2c* (**Q**) and *Snap25* (**R**) on cDKO^POST^ INs. Scale bar in (**F**) and (**O**) = 100 um. N = 3--4 per groups. The quantity of cells used for analysis was included in (**G--I**) and (**P--R**).](elife-54903-fig4){#fig4}

In these experiments, the *Maf* and *Mafb* genes were deleted in the MGE at E10.5 using *Nkx2-1-Cre*. Thus, the CIN phenotypes could be the result of the continuous lack of *Maf* and *Mafb* throughout development and may not necessarily reflect *Maf* and *Mafb* post-mitotic functions. Therefore, we analyzed neuronal morphology in CINs generated from *Maf* cDKOs using *Sst-IRES-Cre*, a *Cre* line that turns on after IN cell cycle exit ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). We found that the *Sst-IRES-Cre* generated *Maf cDKO* had neurite defects similar to those found using *Nkx2.1-Cre*. Thus, *Maf* function in neurite outgrowth is also required post-mitotically.

To identify a postnatal function for *Maf* and *Mafb*, we deleted *both* in neonatal CINs using an in vitro primary culture assay. WT and *Mafb^f/f^; Maf^f/f^;* RosaT^+^ cortical neurons were transfected at DIV1 with a *Cre-*expressing plasmid (driven by the *Dlxi12b* enhancer which is specifically active in forebrain GABAergic neurons). CRE mediated recombination generates tdTomato^+^ cDKOs CINs (cDKO^POST\ (POSTNATAL)^) ([Figure 4J](#fig4){ref-type="fig"}). At DIV14, we performed Sholl analysis, which revealed that cDKO^POST^ INs had reduced neurite complexity, providing evidence that *Maf* and *Mafb* regulate IN morphology postnatally. We then tested whether *Maf*, *Mef2c* and *Snap25* could rescue this phenotype, by co-transfecting *Maf^f/f^; Mafb^f/f^;* RosaT^+^ cells at DIV1 with plasmids expressing *Cre* and either *Maf*, *Mef2c* or *Snap25*. We analyzed the neuronal morphology at DIV14. *Maf*, *Mef2c* and *Snap25* each rescued the neurite outgrowth defect ([Figure 4K--R](#fig4){ref-type="fig"}). Thus, *Maf* and *Mafb* likely promote CIN neurite morphogenesis at postnatal stages through *Mef2c* and *Snap25*.

Prepronociceptin is a HIN marker {#s2-6}
--------------------------------

The DEX analysis revealed that *prepronociceptin* (*Pnoc*) was an upregulated gene in the *Maf* cDKO ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}). A recent study focusing on adult CA1 HIN profiling suggested *Pnoc* is a marker of O-LM INs, a subtype that is mainly *Sst*^+^ ([@bib21]; [@bib3]). Thus, we investigated *Pnoc* expression by FISH in the neonatal hippocampus and cortex ([Figure 5A--H](#fig5){ref-type="fig"}). In P2 WTs, *Pnoc*^+^ cells were largely restricted to the hippocampus ([Figure 5G](#fig5){ref-type="fig"}).\~40% of the *Pnoc*^+^ HINs are tdTomato^+^; very few of them are *Htr3a*^+^ (CGE marker), suggesting that the MGE/POA is the main origin of these HINs (([Figure 5I--M](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). In the *Maf* cDKO there was ectopic *Pnoc* expression in the neocortex (highest in the dorsomedial regions abutting the hippocampus), as well as increased *Pnoc^+^* cells in the hippocampus, consistent with an increased density of HINs ([Figure 5A--L](#fig5){ref-type="fig"}) (WT vs cDKO: Neocortex p\<0.01; dorsomedial Neocortex p\<0.0001; Hippocampus p\<0.01; t test). Indeed, *Sst* FISH and tdTomato^+^ IN quantifications both suggested increased HIN density in the *Maf* cDKO ([Figure 1---figure supplement 7](#fig1s7){ref-type="fig"}, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}).

![*Maf* cDKOs have preferential production of HINs over CINs that are *Pnoc*^+.^\
(**A--F**) Multicolor FISH of *tdTomato*, *Pnoc* and *Htr3a* on P2 WT and cDKO neocortex (**A--B**) and hippocampus (**C--F**). (**G--H**) *Pnoc* expression in the WT and cDKO hippocampus. (**I**) Quantification of the *Pnoc*^+^ INs in the neocortex, dorsal-medial cortex (dmCortex) and hippocampus. (**J**) Quantification of the *Pnoc*^+^; *tdTomato*^+^ INs in the neocortex, dmCortex and hippocampus. (**K**) Quantification of the *Pnoc*^+^ HINs by regions. (**L**) Quantification of the *Pnoc*^+^; *tdTomato*^+^ HINs by regions. (**M**) Quantification of the *Pnoc*^+^; *Htr3a*^+^ HINs by regions. N = 3--4 per group and multiple sections were quantified per animal. Scale bar in (**B**) and (**G**) = 100 um and in (**D**) = 50 um. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001. Welch's t test.](elife-54903-fig5){#fig5}

Together, these data provide evidence that loss of *Maf* and *Mafb* leads to increased production of HINs, which are mainly *Sst*^+^ and/or *Pnoc*^+^. To further test this hypothesis, we studied HIN generation in the cDKO.

*Maf* and *Mafb* repress the generation of HINs {#s2-7}
-----------------------------------------------

Since *Maf* cDKOs have increased density of *Pnoc*, a gene mainly expressed in the HINs, we postulated that *Maf* and *Mafb* together repress HIN generation. To validate the *Nkx2-1-Cre* tdTomato findings ([@bib40]; [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), we quantified CINs and HINs at P2 using *Lhx6*^+^ FISH. *Lhx6* marks MGE-derived INs ([@bib9]; [@bib26]). *Lhx6*^+^ CIN density was decreased in *Maf* cDKOs as previously reported ([@bib40]; [Figure 6B](#fig6){ref-type="fig"}). Consistent with our hypothesis, there was an increased density of *Lhx6*^+^ HINs across all hippocampal regions in the *Maf* cDKO (p\<0.05; Welch's t test) ([Figure 6C](#fig6){ref-type="fig"}). Furthermore, there was an increased density of *Sst*^+^ HINs cell density in all hippocampal regions (CA1:\~1.5 fold; p\<0.001, CA3 and DG:\~2 fold; p\<0.0001) ([Figure 1---figure supplement 7](#fig1s7){ref-type="fig"}).

![*Maf* cDKOs overproduce INs that will become HINs.\
(**A**) Schema depicting the BrdU/EdU pulse-chase experiment. Briefly, BrdU was injected into a pregnant mouse at E12.5 and EdU was injected at E15.5. Neonatal pups were harvested at P2 analyzed for *Lhx6*/BrdU, *Lhx6*/EdU co-expression. (**B**) Quantification of *Lhx6*^+^ IN cell density in the P2 neocortex. (**C**) Quantification of *Lhx6*^+^ IN cell density in the P2 hippocampus by region. (**D--G**) *Lhx6* FISH with BrdU (D-E, early-born) or EdU (F-G, late-born) co-labeling in P2 WT and cDKO hippocampus. (**H--I**) Quantification of the *Lhx6*^+^; BrdU^+^ IN cell density in the hippocampus by region (**H**) and in total (**I**). (**J--K**) Quantification of the *Lhx6*^+^; EdU^+^ IN cell density in the hippocampus by region (**J**) and in total (**K**). N = 3 per group and multiple sections were quantified per animal. Scale bar in (**E**) = 100 um. Welch's t test.](elife-54903-fig6){#fig6}

Next, to test if *Maf* cDKOs generate more HINs at specific developmental stages, we conducted EdU/BrdU pulse-chase experiments. Pregnant mice were injected with BrdU at E12.5, and subsequently with EdU at E15.5. The animals were harvested at P2 to study co-expression of *Lhx6* with BrdU and EdU ([Figure 6A](#fig6){ref-type="fig"}). We compared the generation of CINs and HINs.

At E12.5 (early-born; *Lhx6*^+^;BrdU^+^), we observed \~2 fold increase in HIN generation in the *Maf* cDKO (p\<0.01; t test). The increase was similar across all hippocampal subregions ([Figure 6D, E, H and I](#fig6){ref-type="fig"}) (CA1: p=0.02; CA3: p\<0.001; DG: p\<0.01; t test). In contrast, *Maf* cDKOs had a trend toward decreased CIN generation at E12.5 ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). At E15.5 (late-born; *Lhx6*^+^;EdU^+^), we observed \~2.5 fold increase in HIN production (p\<0.0001; t test). Similarly, the increase was across all hippocampal subregions ([Figure 6F, G, J and K](#fig6){ref-type="fig"}) (CA1: p\<0.001; CA3: p\<0.05; DG: p\<0.01; t test). We further quantified the ratio of HIN density over CIN density by age and by genotypes. In WTs, the MGE tends to generate HINs/CINs in a 1:2 ratio at both E12.5 and E15.5. In cDKOs, the MGE overproduces HINs, especially at E12.5 ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Together, these data support the hypothesis that loss of *Maf* and *Mafb* leads to HIN overproduction perhaps at the expense of generating CINs.

Discussion {#s3}
==========

*Maf* (*c-Maf*) and *Mafb* are co-expressed in the MGE and its lineages. Previously, to elucidate how *Maf* and *Mafb* regulated CIN and HIN development, we compared the transcriptomes of WT and *Maf* cDKO using bulk RNA-seq from E13.5 MGEs -- this approach failed to identify differentially expressed genes (data not shown) probably because of the heterogeneity of the tissue. Here, we applied scRNA-seq to compare the transcriptomes of P0 WT and *Maf* cDKO neocortex and hippocampus. Through this approach, we successfully identified genes that were differentially expressed in pallial INs. Our experimental analyses provided evidence that some of the DEX genes contribute to *Maf* cDKO phenotypes: (1) reduced *Mef2c* expression contributed to overproduction of SST^+^ CINs and under production of PV^+^ CINs ([Figure 1](#fig1){ref-type="fig"} and [Figure 2](#fig2){ref-type="fig"}); (2) reduced *Snap25* and *Mef2c* contribute to defects in IN morphology ([Figure 4](#fig4){ref-type="fig"}); (3) reduced *Cxcr4* expression led to defects in IN migration and lamination ([Figure 1---figure supplement 6](#fig1s6){ref-type="fig"}). We also discovered that the *Maf* cDKO MGE preferentially generates HINs over CINs ([Figure 5](#fig5){ref-type="fig"} and [Figure 6](#fig6){ref-type="fig"}). To our knowledge, this may be the first identification of genes that control the differential production of HINs and CINs.

Identification of genes that are candidate markers of immature PV INs {#s3-1}
---------------------------------------------------------------------

Our scRNA-seq analysis not only identified DEX genes between WT and cDKOs, but also provided evidence for molecular markers of immature pallial INs, especially for the PV^+^ subtype, which has been elusive to identify before adolescence. Comparison of *Sst*^+^ and *Sst*^-^ P2 INs identified sets of genes that were differentially expressed between the two groups, including *Arl4d*, *distal-less homeobox 5* (*Dlx5*), *Elmo1,* Erb-B2 receptor tyrosine kinase 4 (*Erbb4*), *Igfbp4, Mef2c*, *Sp9* and *Tcf12* ([Figure 3](#fig3){ref-type="fig"}). Because *Sst-IRES-Cre* fate mapping into adulthood shows that *Sst-IRES-Cre* expression marks almost all SST^+^ INs and \<10% of PV INs ([@bib40]), we hypothesize that P2 *Sst^-^* INs primarily represent neurons that will become PV^+^ ([@bib12]). We used multicolor FISH to compare the expression of genes in P2 *Nkx2.1*-lineage *Sst*^+^ and *Sst*^-^ INs. We validated that *Elmo1, Igfbp4*, *Mef2c* and *Sp9* may be candidate markers for immature PV^+^ INs ([Figure 3](#fig3){ref-type="fig"}), especially for immature HINs that likely become PV^+^. This is particularly important and useful for future research that aims to identify different molecular mechanisms involved in PV versus SST HIN development.

Of note, here we report that \~22% of the *Nkx2.1-Cre* lineage CINs are *Sp9* positive at P2. To our knowledge, this is the first report to show *Sp9* expression in CINs in the *Nkx2.1-Cre* lineage. We agree that 22% may be an underestimate because of several reasons: (1) when we looked at the *Sp9* expression in the hippocampus,\~60% of the PV candidate INs are *Sp9* positive; (2) the robustness of the *Sp9* RNAscope probe seemed to be stronger in the hippocampus region; (3) the robustness and efficiency of the *Sp9* RNAscope probe is not as strong as the traditional DIG-labeled *Sp9* probe in the neocortex as reported by the Allen Brain Institute. Additionally, recent studies have emerged to study the role of *Sp9* in IN development ([@bib27]; [@bib59]). Liu et al reported around 50% PV^+^ *Nkx2.1-Cre* lineage CIN loss in adulthood when comparing *Nkx2.1-Cre-*generated *Sp9* conditional heterozygous and homozygous (cHet and cKO) mutants. However, it may be questionable to conclude that 50% of the PV CINs are *Sp9^+^* due to the fact that *Sp9* deletion also leads to 50% total loss of *Nkx2.1-Cre* lineage CINs ([@bib27]). While more studies are needed to validate the roles of these candidate PV IN marker genes in PV IN development and maturation, recent reports on *Sp9* and *Mef2c* have provided a genetic foundation for our discovery of early candidate PV IN markers ([@bib27]; [@bib36]; [@bib59]).

*Mef2c* expression driven by *Maf* and *Mafb* promotes PV IN production and morphological maturation {#s3-2}
----------------------------------------------------------------------------------------------------

*Mef2c* is a high confidence risk gene for ASD, intellectual disability(ID) and schizophrenia ([@bib61]). Notably, *Mef2c* has roles in promoting cortical excitatory neuron synapse formation and morphology maturation ([@bib20]). Furthermore, there is evidence that *Mef2c* marks PV IN precursors, and is required for PV IN development ([@bib36]).

*Mef2c* is one of the most down-regulated genes in *Maf* cDKO MGE derived INs, which we confirmed using immunofluorescence analysis in the P2 *Maf* cDKO neocortex ([Figure 1](#fig1){ref-type="fig"}, [Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}). *Mef2c* rescued the IN neurite outgrowth defect of both prenatal and postnatal *Maf* cDKO INs ([Figure 4](#fig4){ref-type="fig"}). Thus, *Mef2c* promotes IN morphological maturation, similar to its functions in excitatory neurons ([@bib20]).

Deletion of *Mef2c* using *Dlx5/6-Cre* led to a preferential loss of PV CINs, similar to the *Maf* cDKO phenotype ([@bib36]; [@bib40]). Here we found that transduction of *Mef2c* into *Maf* cDKO MGE cells largely rescued their deficit in generating PV CINs ([Figure 2](#fig2){ref-type="fig"}).

The *Maf* cDKO MGE generates \~2 fold increase in SST^+^ CINs born at E12.5 and at E15.5, probably at the expense of generating PV^+^ CINs ([Figure 1](#fig1){ref-type="fig"}; [@bib40]; [Scheme 1](#C1){ref-type="fig"}). Thus, in the absence of the *Maf* genes, the MGE has a persistent defect in generating the proper balance of SST/PV INs. We propose a transcriptional pathway in which *Maf* and/or *Mafb* drive *Mef2c* expression in MGE progenitors to promote PV IN production ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). This pathway may operate in conjunction with signaling hubs such as MTOR/MAPK/RYK, as perturbation in these pathways also lead to altered PV/SST expression ([@bib33]; [@bib37]; [@bib2]). Thus, cellular signaling as well as the *Mafs* and *Mef2c* are critical components of the program driving PV IN development.

*Maf*, *Mafb* and *Mef2c* expression persist as INs migrate into and mature in the pallium. Neonatal deletion of *Maf* and *Mafb* led to reduced neurite outgrowth, a defect rescued by *Mef2c* transduction ([Figure 4](#fig4){ref-type="fig"}). Thus, our proposed *Maf*/*Mafb*→ *Mef2c* transcription pathway persists as INs mature postnatally. Future work should explore whether adult *Maf*/*Mafb* expression continues to control *Mef2c* and IN function ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}. Model).

Mechanisms that underlie PV vs SST IN neurogenesis {#s3-3}
--------------------------------------------------

While our results support that *Maf* and *Mafb* have important roles in regulating the balance of PV vs. SST IN neurogenesis in the SVZ of MGE (this report and [@bib40]), other studies suggest a different hypothesis in which PV INs are primarily generated by the MGE SVZ progenitors, while SST INs are primarily generated by the MGE VZ progenitors ([@bib19]; [@bib28]; [@bib43]). In particular, Petros et al showed that more SST INs are produced when MGE progenitors stay in the VZ (basal progenitor), while more PV INs are produced when MGE progenitors stay longer in the SVZ phase (intermediate progenitor). While the experimental design and results are compelling, the study is based on the hypothesis that MGE-derived IN fates are determined by the progenitor cell cycle stage. Our data showed that *Maf* and *Mafb* expression starts in the MGE SVZ. Deletion of *Maf* and *Mafb* leads to overproduction of SST INs at the expense of PV INs, but not a total loss of PV INs. Therefore, we propose the hypothesis that MGE progenitors have the potential to generate different types of INs through distinct transcriptomic regulation. Future studies are certainly needed to better understand these two hypotheses.

*Snap25* expression driven by *Maf* and *Mafb* promotes MGE-derived IN morphological maturation {#s3-4}
-----------------------------------------------------------------------------------------------

*Snap25* is part of the neuronal SNAP receptor (SNARE) complex which regulates vesicle fusion, receptor trafficking and neurite branching ([@bib13]; [@bib56]). *Snap25* loss of function studies in hippocampal excitatory neurons causes defects in neurite outgrowth and neuronal survival ([@bib13]).

*Snap25* expression was decreased in the *Maf* cDKO INs ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}). Expressing *Snap25* in prenatal and postnatal *Maf* cDKO INs, rescued their neurite outgrowth defect, similar to what was observed with *Mef2c* ([Figure 4](#fig4){ref-type="fig"}). Thus, *Maf* and *Mafb* driven expression of both *Snap25* and *Mef2c* are critical aspects of how the *Maf* genes regulate IN development. Since each gene could rescue these phenotypes, it is possible that they may regulate each other.

*Maf* and *Mafb* repress HIN production and thereby control the balance of CIN and HIN numbers {#s3-5}
----------------------------------------------------------------------------------------------

*Maf* cDKOs had increased numbers of HINs ([Figure 5](#fig5){ref-type="fig"}). BrdU and EdU birth-dating provide evidence that the cDKO generates more HIN at both early and late stages of MGE neurogenesis ([Figure 6](#fig6){ref-type="fig"}).

The molecular program that distinguishes CINs from HINs generated by the MGE remains largely unknown. Herein via scRNA-seq, we identified that *Pnoc*, a gene encoding prepronociceptin, may be a unique marker that distinguishes HINs from CINs. *Pnoc* was previously described as an IN marker ([@bib46]; [@bib53]). In a more recent scRNA-seq analysis from hippocampal tissue, *Pnoc* expression was found enriched in O-LM HINs ([@bib21]). Our ISH analysis from P2 WTs demonstrated that *Pnoc* is widely and robustly expressed in HINs but not CINs ([Figure 5](#fig5){ref-type="fig"}). Furthermore, *Pnoc* expression is strongly upregulated in the hippocampus in the cDKO ([Figure 5](#fig5){ref-type="fig"}), consistent with evidence for increased HIN generation.

Altogether, our data suggests that *Maf* and *Mafb* control the CIN/HIN ratio by putting a brake on HIN generation. As a result, the cDKOs have a disproportionate number of HINs. Thus, in addition to controlling the SST/PV IN subtype fate decision, *Maf* and *Mafb* also control CIN/HIN regional fate determination.

Decreased *Cxcr4* expression in the *maf* cDKO may alter IN laminar positioning {#s3-6}
-------------------------------------------------------------------------------

Our scRNA-seq data suggested that *Cxcr4* expression was reduced in neonatal *Maf* cDKO MGE INs ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}). Indeed, FISH at P2 showed clear reduction of *Cxcr4* expression in *Maf* cDKO, especially in the hippocampus (CA1, CA3 and DG p=0.0159; Neocortex p\<0.0001; t test) ([Figure 1---figure supplement 6](#fig1s6){ref-type="fig"}). *Cxcr4* expression reduction starts as early as E15.5 (p=0.012; t test) ([Figure 1---figure supplement 6](#fig1s6){ref-type="fig"}). These provide evidence for a potential mechanism underlying premature IN entrance into the cortical plate, that we reported previously ([@bib40]).

Note that *Cxcr4* null mice did not show IN over-migration or over-production in the hippocampus ([@bib47]; [@bib55]; [@bib64]; [@bib24]). While lacking *Cxcr4* in the cDKO would lead to disruption in the IN chemotactic migration, reduced *Cxcr4* alone probably does not explain why *Maf* cDKOs have more HINs.

Potential mechanisms that lead to an increased HIN/CIN ratio in the *maf* cDKO {#s3-7}
------------------------------------------------------------------------------

DE analysis suggested that *Nrp1* is upregulated in the cDKO ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}). FISH showed higher *Nrp1* expression in the P2 cDKO hippocampus ([Figure 1---figure supplement 7](#fig1s7){ref-type="fig"}). Semaphorin binding to the *Nrp1* receptor is implicated in MGE-derived IN migration away from the striatum ([@bib34]). Semaphorin/neuropilin signaling is also implicated the generation and migration of CINs ([@bib1]; [@bib57]). However, we are unaware of a study that focused on *Nrp1*'s role in promoting the production/migration of HINs vs CINs.

We hypothesized that the increase in *Nrp1* expression might affect CIN/HIN migration or regional fate in the cDKO. We tested this idea by introducing *Nrp1* expression into MGE WT progenitors at E12.5. We transplanted MGE immature INs carrying higher expression of *Nrp1* into the P1 neocortex, and surveyed their final cortical destination at P21. The majority of these modified INs appear to remain as an aggregate at the transplantation site. Very few of them migrated within the neocortex or to the hippocampus (data not shown). These results suggest that an increase in *Nrp1* expression alone is not sufficient to promote the increased HINs/CIN ratio.

Interestingly, *Nrp1* is not only a receptor for semaphorins, but also for vascular endothelial growth factor (VEGF). There is evidence that VEGF is expressed in the developing cortex and may regulate IN migration ([@bib5]). Mackenzie and Ruhrberg et al. extensively reviewed the functions of VEGF in the nervous system ([@bib31]), which includes regulating neurogenesis ([@bib23]), neuronal migration ([@bib48]) and axonal guidance ([@bib15]). In the developing mouse brainstem, VEGF guides somata migration of NRP1-expressing facial motor neurons ([@bib48]). In the visual system, VEGF serves as a chemoattractant to NRP1-expressing retinal ganglionic cells to promote contralateral axonal extension ([@bib15]). Another study further suggested that VEGF-NRP1 binding works in conjunction with CXCR4-SDF1 to promote breast cancer cell invasion/metastasis ([@bib4]).

Thus, while the change of *Cxcr4* and *Nrp1* expression in the *Maf* cDKO alone does not provide a clear mechanism for why the mutant generates more HINs, we propose that interactions between NRP1 and CXCR4 can guide IN migration, and that in this context, increases in NPR1 signaling may guide INs to the hippocampus.

*Maf* cDKOs exhibit seizures - disease implications of *Maf* and *Mafb* dysfunction {#s3-8}
-----------------------------------------------------------------------------------

EEG recordings from freely behaving mice showed that *Maf* cDKOs exhibit frequent spike-and-wave-discharges ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) similar to those that have been previously described in mouse models of genetic *absence* type epilepsy ([@bib11]; [@bib41]; [@bib51]; [@bib52]). The cellular and molecular mechanisms underlying this are undoubtedly multifaceted, and include the overall reductions in MGE-derived CINs and HINs in the adult *Maf* cDKO mutant ([@bib40]). Furthermore, we identified several genes regulated by *Maf* and *Mafb*, including *Mef2c*, *Snap25* and *Npy*, mutations of which could lead to seizures ([@bib10]; [@bib20]; [@bib22]). Moreover, human patients with *Maf* mutations exhibit seizures and ID ([@bib39]).

In summary, we identified genetic targets (e.g. *Mef2c*, *Snap25*, *Cxcr4*) that are downstream of *Maf* and *Mafb*. While *Maf* and *Mafb* themselves are not high confidence neuropsychiatric disease genes, they are key regulators of many disease genes that are responsible for balanced MGE SST and PV IN production (*Mef2c*), IN morphological maturation (*Mef2c*, *Snap25*), and balanced MGE CIN and HIN production (*Cxcr4*, *Nrp1*).

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\             Designation                                      Source or reference   Identifiers                                                        Additional information
  (species) or resource                                                                                                                                               
  ------------------------- ------------------------------------------------ --------------------- ------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------
  Genetic reagent\          *Mafb^f/f^*                                      [@bib69]                                                                                 Generous gift from Dr. Lisa Goodrich
  (*M. musculus*)                                                                                                                                                     

  Genetic reagent\          *Maf^f/f^*                                       [@bib65]                                                                                 Generous gift from Dr. Carmen Birchmeier
  (*M. musculus*)                                                                                                                                                     

  Genetic reagent\          *Nkx2.1-Cre*                                     [@bib67]              Jax labs \#008661                                                  
  (*M. musculus*)                                                                                                                                                     

  Genetic reagent\          *Sst-IRES-Cre*                                   [@bib58]              Jax labs \#013044                                                  
  (*M. musculus*)                                                                                                                                                     

  Genetic reagent\          *Ai14 Rosa26-tdTomato (RosaT)*                   [@bib32]              Jax labs \#007908                                                  
  (*M. musculus*)                                                                                                                                                     

  Antibody                  Rabbit anti-PARVALBUMIN\                         Swant                 PV27\                                                              1:400 dilution; no need for antigen retrieval
                            (polyclonal)                                                           RRID:[AB_2631173](https://scicrunch.org/resolver/AB_2631173)       

  Antibody                  Rat anti-SOMATOSTATIN\                           Millipore Sigma       MAB354\                                                            1:200 dilution; works well in low fixed tissue
                            (monoclonal; clone YC7)                                                RRID:[AB_2255365](https://scicrunch.org/resolver/AB_2255365)       

  Antibody                  Rabbit anti-MEF2C\                               Proteintech           10056--1-AP\                                                       1:500 dilution; no need for antigen retrieval
                            (polyclonal)                                                           RRID:[AB_513447](https://scicrunch.org/resolver/AB_513447)         

  Antibody                  Rat anti-BrdU antibody\                          Abcam                 Ab6326\                                                            1:500 dilution; BrdU was stained after FISH procedure (proteinase K-based antigen retrieval)
                            (monoclonal \[BU1/75(ICR1)\]                                           RRID:[AB_305426](https://scicrunch.org/resolver/AB_305426)         

  Antibody                  Sheep anti-DIG-POD antibody\                     Millipore Sigma       11207733910\                                                       1:1000 dilution
                            (polyclonal)                                                           RRID:[AB_514500](https://scicrunch.org/resolver/AB_514500)         

  Antibody                  Sheep anti-Fluorescein-POD antibody\             Millipore Sigma       11426346910\                                                       1:1000 dilution
                            (polyclonal)                                                           RRID:[AB_840257](https://scicrunch.org/resolver/AB_840257)         

  Antibody                  Chicken anti-GFP (polyclonal)                    Aves                  GFP-1020\                                                          1:1000 dilution
                                                                                                   RRID:[AB_100000240](https://scicrunch.org/resolver/AB_100000240)   

  Commercial assay or kit   Click-iT EdU kit                                 Life Technologies     Cat \#C10340                                                       Follow the manufacturer's instruction

  Commercial assay or kit   RNAscope multiplex fluorescent kit (version 2)   ACD Bio               Cat \#323120                                                       Follow the manufacturer's instruction

  Commercial assay or kit   Mm-*Igfbp4*                                      ACD Bio               Cat \#425711                                                       Follow the manufacturer's instruction and used it with the RNAscope multiplex fluorescent kit (version 2)

  Commercial assay or kit   Mm-*Sst*                                         ACD Bio               Cat \#404631                                                       

  Commercial assay or kit   Mm-*Sp9*                                         ACD Bio               Cat \#564531                                                       

  Commercial assay or kit   Mm-*Mef2c*                                       ACD Bio               Cat \#421011                                                       

  Commercial assay or kit   Mm-*Tcf12*                                       ACD Bio               Cat \#504861                                                       

  Commercial assay or kit   Mm-*tdTomato*                                    ACD Bio               Cat \#317041                                                       

  Commercial assay or kit   Mm-*Pnoc*                                        ACD Bio               Cat \#437881                                                       
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Animals {#s4-1}
-------

All procedures and animal care were approved and performed in accordance with the University of California San Francisco Laboratory Animal Research Center (LARC) guidelines. All mice strains have been previously published: Ai14 Rosa 26-tdTomato *Cre*-reporter ([@bib32]), *Nkx2.1-Cre* ([@bib67]), *Sst-IRES-Cre* ([@bib58]), *Mafb* flox ([@bib69]) and *Maf* flox ([@bib65]). Mice were back-crossed onto a CD-1 background before analyses. For timed pregnancies, noon on the day of the vaginal plug was counted as embryonic day 0.5.

EdU/BrdU injections and analysis {#s4-2}
--------------------------------

For pulse-chase experiments, pregnant mice were pulsed with 5-Bromo-2'-deoxyuridine (BrdU, Sigma B5002, prepared at 20 mg/ml) at E12.5 at a dose of 50 mg BrdU/kg body weight and 5-Ethynyl-2′-Deoxyuridine (EdU, Thermo fisher Scientific E10187, prepared at 10 mg/ml) at E15.5 at a dose of 40 mg EdU/kg body weight. Progeny were sacrificed at P2. BrdU^+^ cells were visualized using anti-BrdU antibody (Abcam, \#ab6326). EdU^+^ cells were visualized using standard procedures from the Clik-iT EdU plus kit (Thermo Fisher Scientific C10340). Of note, BrdU staining was done following *Lhx6* FISH. Since the tissues were processed mainly for FISH, tissue permeabilization was done using proteinase K for 30 mins. There was no hydrogen chloride (HCl) treatment for the tissue. This step likely decreased the sensitivity of the BrdU antibody. Although the BrdU antibody we used has been reported previously for the cross-reactivity with EdU, since we skipped the HCl pre-treatment, we did not observe much cross-reactivity, especially in the *Lhx6^+^* IN population.

Immunofluorescence/Immunohistochemistry {#s4-3}
---------------------------------------

All P2 animals were perfused with 4% PFA, followed by 4% PFA overnight fixation. Tissues were transferred to 30% sucrose the next day for cryoprotection. Brains were embedded with OCT and tissues were sectioned coronally at 25 µm. Sections were all mounted onto glass slides before staining or ISH procedures. To perform immunofluorescence staining, all primary and secondary antibodies were diluted in PBS containing 2.5% BSA and 0.3% Triton X-100. For all experiments, primary antibodies were incubated with tissue overnight, while secondary antibodies were incubated for at least 2 hr in room temperature (RT). Immunofluorescent labeling was performed with the following primary antibodies: rabbit anti-parvalbumin (Swant PV27; 1:400), rat anti-somatostatin (Millipore MAB354; 1:400), rabbit anti-MEF2C (proteintech 10056--1-AP). The appropriate 488, 594 or 647 Alexa-conjugated secondary antibodies (1:800-1:1000) were from Life Technologies. After the staining, sections were cover slipped with Vectashield containing DAPI (Vector labs; H-1800).

Fluorescent In situ hybridization (FISH) and standard ISH {#s4-4}
---------------------------------------------------------

To generate riboprobes for target genes, cDNAs were PCR amplified from a homemade mouse cDNA library synthesized from P0 neocortex using Superscript II. The 5' and 3' primers while containing sequences for cDNA synthesis, also introduced ClaI and XbaI restriction enzymes sites. The PCR products and the vector, pSP73 (Promega Cat \# P2221), were digested with ClaI and XbaI, and then ligated using T4 ligase. The RNA anti-sense fluorescein-labeled/Digoxigenin-labeled probe was generated by T7 RNA polymerase (Roche) and Fluorescein labeling kit (Roche)/DIG labeling kit (Roche) from a NdeI linearized vector, with the size of the probe usually between \~600--800 bp. Briefly, 40 um sections were digested with proteinase K for 20 mins followed by 4% PFA post-fixation and 3% H2O2 incubation to block endogenous peroxidase. Hybridization with DIG and/or Fluorescein-labeled probes were performed in prehybridization buffer at 65°C overnight. Standard ISH was amplified with BM purple after anti-DIG-AP labeling, while FISH signals were performed following TSA plus kit (Akoya Biosciences) protocol after anti-DIG-POD or anti-Fluorescein-POD labeling. Detailed materials and steps can be found as previously published ([@bib14]).

RNAscope multi-color fluorescent in situ hybridization {#s4-5}
------------------------------------------------------

Tissues were all sectioned at 25 um and mounted onto microscope slides before the experiment. The day before the experiment, tissues were defrosted and baked at 60°C for an hour for better attachment followed by PFA post-fixation at 4°C overnight. The in situ hybridization was performed following ACD protocol for the multiplex fluorescent kit (version 2). The RNAscope probes were as follows: Mm-Igfbp4 (Cat. 425711), Mm-Sst (Cat. 404631), Mm-Sp9 (Cat. 564531), Mm-Mef2c (Cat. 421011), Mm-Tcf12 (Cat. 504861), tdTomato (Cat. 317041) and Pnoc (Cat. 437881). Slides were mounted with Vectashield mounting media containing DAPI (Cat. H-1800). For the PV marker discovery experiment, we used multiple sections from 2 WT animals for validation and quantification.

Single cell RNA-seq sample and library preparation {#s4-6}
--------------------------------------------------

For single cell dissociation, primary neocortex tissues were dissected (1 P0 WT and 1 P0 cDKO; age and gender matched), and incubated with a pre-warmed solution of Papain (BrainBits) prepared according to manufacturer's instructions for 15 min at 37°C. After incubation, tissues were washed with DMEM/10% FBS (Thermo Fisher) solution multiple times, followed by gentle trituration. Samples were diluted to approximately 2,000 cells per microliter. Cell concentration was confirmed using a CountessII automatic hemocytometer before loading onto a 10X genomics single cell preparation platform following manufacturer's instruction to target 10,000 cell recovery per sample. Library preparation was performed by UCSF Institute of Human Genetics Core (IHG), using 10X Chromium Single 3' Reagent Kits Version 2 (10X Genomics). The library length and concentration were quantified using a Bioanalyzer (Agilent) according to manufacturer's protocol. Paired-end sequencing was performed on the Illumina NovaSeq.

Processing of sequencing reads {#s4-7}
------------------------------

Raw base call (BCL) files were converted into FASTQ files and demultiplexed to align cells with their own barcodes using Cell Ranger V.2. Transcriptome alignment (mm10), cell filtering, barcode counting, UMI counting as well as matrix data output for downstream clustering and differential expression analyses were also performed using Cell Ranger V.2 following manufacturer's manual. Up to this point, the pipeline was completely ran by UCSF IHG computational core.

Cell clustering, *t*-SNE/UMAP visualization and marker-gene identification {#s4-8}
--------------------------------------------------------------------------

A digital gene expression matrix was constructed from the raw sequencing data as described using Cell Ranger. Cells with fewer than 500 UMIs or over 20,000 UMIs were discarded. Downstream analyses were performed with Seurat v.2 and the R package ([@bib7]; [@bib54]). First, cells that have genes with very few counts or cells that were with high mitochondrial genes were filtered out for the downstream analyses. Gene expression value was normalized based on Seurat pipeline suggestion. Briefly, the 'LogNormalize' command normalizes the feature barcode (UMI) expression measurements by the total batch UMI counts; the outputs were multiplied by a scale factor of 10,000 and log-transformed. After normalization, data were scaled based on cell-cell variation regression (we called these numbers normalized expression level) to minimize the unwanted variations likely coming from technical noise or batch effects. The top \~1000 genes with the highest variance were selected to perform principal component analysis (PCA) for dimensionality reduction. 20 PC components were used to perform Louvain clustering with resolution = 1.0 to generate t-SNE plot for cluster visualization. 24 clusters were identified. We then performed FindAllMarker function from Seurat to identify markers for each cluster. Clusters were assigned to known cell types based upon cluster-specific markers. DE genes between WT and cDKO were performed per cluster basis using MarkerComp function. DE genes with adjusted p-value less than 0.05 and \|LogFC\| \> 0.3 were selected to perform ISH for validation and functional studies. Of note, we also performed unsupervised clustering, marker gene identification, DEX analysis and UMAP visualization using Scanpy with Python ([@bib66]). We found consistent results between the two unbiased analyses.

MGE transplantation {#s4-9}
-------------------

A detailed protocol for this procedure is available in a methods format ([@bib62]; [@bib63]). We bred male mice that would yield embryos carrying *Ai14* and either WT (*Ai^Flox/Flox^*) or homozygous (*Maf^Flox/Flox^; Mafb^Flox/Flox^*; RosaT*^+^*) for both of the *Maf* alleles. The embryos were collected at E13.5, dissociated and then transfected either with a *DlxI12b-Cre* expressing vector or both *DlxI12b-Cre* expressing and target gene expressing vectors ([@bib62]; [@bib63]) in DMEM supplemented with 10% Fetal Bovine Serum (FBS) at 37°C and at pH \~7.2 for 30 min. The successful delivery of the *Cre* DNA will deletes the *Maf* genes and activates tdTomato expression from the *Ai14* allele. The cells were then washed several times with DMEM/FBS and pelleted. Next, the cells were loaded into the front of a beveled glass needle. P1 WT pups were anesthetized on ice and injected with \~300 nL of cells over 3--5 sites in the right hemisphere. Pups were warmed until able to move and then put back with their mom. They were aged to 30 days and then perfused. Note that we section whole brains of all tissues into 25 um sections, and we used all brain sections for PV and SST staining followed by cell quantification.

Primary neuronal culture for analysis of dendritic arborization (Sholl) using neonatal cortex {#s4-10}
---------------------------------------------------------------------------------------------

Primary cortical neuron cultures were prepared as described ([@bib49]). Briefly, we bred *Maf^Flox/Flox^*, *Mafb^Flox/Flox^* RosaT*^+^* females with *Maf^Flox/+^*, *Mafb^Flox/+^, Nkx2-1 Cre^+^* males to generate P0 *Maf* cKO, *Mafb* cKO and cDKOs. Control P0 animals were generated either through the same crossing or through *Ai14f^Flox/Flox^* females bred with *Nkx2-1 Cre^+^* males. tdTomato^+^ P0 pups were pre-screened using fluorescence dissection microscope. We also collected some tdTomato^-^ P0 pups for cell preparation. Cortical tissues were dissected in cold EBSS, followed by trypsin (Thermo Fisher Scientific 25200056) treatment for 15 min at 37°C. Trypsinization was inhibited using 10% FBS containing DMEM. Cells were washed once with DMEM, then resuspended in 10% FBS containing Neuralbasal-A medium (Thermo Fisher Scientific 12348017) with B27 (Thermo Fisher Scientific 17504044). Cell density was quantified using hemocytometer. tdTomato^+^ cell preparations were diluted using tdTomato^-^ P0 cell preparation roughly at a ratio of 1:10. Cells were plated onto poly-D-lysine and laminin coated coverslips (Corning 08-774-385) preloaded in 24-well plates and then cultured in a 37°C incubator for 14 days. Serum free Neuralbasal-A medium with B27 and Glutamax (Thermo Fisher Scientific 35050061) was used to maintain the cell growth. After 14 days in vitro, cell culture medium was removed and replaced with freshly made 4% PFA for 15 min fixation. PFA was washed off several times with 1X PBS followed by a regular immunostaining protocol. For Sholl analysis,≥3 animals and 15--20 neurons were analyzed per genotype. Images were processed and analyzed using FIJI software based on previously described protocol ([@bib40]; [@bib16]; [@bib35]).

EEG recordings and analysis {#s4-11}
---------------------------

EEG recordings and analysis were done as previously described ([@bib8]; [@bib44]). The devices for EEG recordings in freely behaving mice were all custom made in the Paz lab. Briefly, we designed devices containing multiple screws for acquisition of the EEG signals implanted in primary somatosensory (S1), primary visual (V1), and prefrontal cortices. S1: −0.5 mm posterior from Bregma,±3.25 mm lateral. V1: −2.9 mm posterior from Bregma,±2.5 mm lateral. PFC: 1 mm anterior from Bregma, midline. Mice were allowed to recover for at least 1 week before recording. EEG signals were recorded using RZ5 (TDT) and sampled at 1221 Hz. A video camera that was synchronized to the signal acquisition was used to continuously monitor the animals. Each recording trial lasted 30--180 min. To control for circadian rhythms, we housed our animals using a regular light/dark cycle, and performed recordings between roughly 11:00 AM and 6:00 PM. All the recordings were performed during wakefulness.

Image acquisition and processing {#s4-12}
--------------------------------

1.  Immunohistochemistry images were taken using 10X or 20X objectives under Nikon Ti microscope with DS-Qi2 color camera together with NIS Elements acquisition software. Image brightness and contrast were adjusted and merged for publication using FIJI software.

2.  Sholl analysis and excitatory synapse images were taken using the Nikon Ti inverted fluorescence microscope with CSU-W1 large field of view confocal. Images for Sholl analysis were taken using 40X oil objective. Open source micromanager 2.0 beta was used to acquire images. Brightness/contrast adjustment, z-stack image and binary image processing and Sholl analysis were all conducted using the image calculator and Sholl analysis plugins in FIJI software.

Schema and Model Illustration {#s4-13}
-----------------------------

All schemas were drafted using the BioRender online platform.

Quantification and statistical analyses {#s4-14}
---------------------------------------

All bar graphs were shown as mean ± SEM. All statistical analyses were performed using Graphpad Prism (version 7) and a p value of \< 0.05 was considered significant. For RNA expression comparison shown in [Figure 3](#fig3){ref-type="fig"}, we used python to conduct non-parametric analysis, and a p value of \< 0.05 was considered significant. The specific n for each experiment as well as the post-hoc test and corrected p-values, can be found in the Results section, in the Figure legends or in supplementary tables.

For all cell counts performed for immunohistochemistry and in situ hybridization, we used the cell counter plug-in in FIJI software. For P2 hippocampus immunofluorescence and FISH cell counts, we focused on the central part of the hippocampi (exclude very rostral and very caudal region). Note that for P2 HIN *Nrp1* FISH, we excluded the pyramidal cell layer of hippocampi for quantification. The *Nrp1* expression is very high in the hippocampal excitatory neurons (pyramidal layer) and we think that might confound the analysis.

For statistical analyses, we mainly used two methods depending on whether data were parametric or nonparametric in distribution. For parametric data, we utilized a Welch's t test. For data that was normalized (eg. proportions), we used the non-parametric Mann-Whitney test. For MGE transplantation, we used non-parametric *Chi*-square test for comparison.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

Through detailed analysis of the *Maf/Mafb* double mutant mice, the manuscript uncovers a set of transcriptionally regulated genes of MGE-derived cortical and hippocampal interneurons. The manuscript combines single cell sequencing and transplantation rescue assay. The results demonstrate arole for these genes in interneuron fate and maturation in part through regulating transcription of neuropsychiatric disease genes.

**Decision letter after peer review:**

Thank you for submitting your article \"*Mafb* and *c-Maf* control pallial interneuron fate and maturation through regulation of neuropsychiatric disease genes\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Marianne Bronner as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Stewart Anderson (Reviewer \#1).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. In recognition of the fact that revisions may take longer than the two months we typically allow, until the research enterprise restarts in full, we will give authors as much time as they need to submit revised manuscripts.

Summary:

In this manuscript, the authors examine the role of *Mafb* and c-*Maf* in the generation of subsets of cortical (CINs) and hippocampal interneurons (HINs). By performing a double conditional knock out using *Nkx2.1-cre*, they then perform single cell RNA-seq analysis on P0 neocortex from wildtype and cDKO animals, revealing upregulation (*Pnoc* and *Sst*) and downregulation (*Mef2c*, *Snap25* and *Nxph1* and *2*) genes. These hits were verified by multi-channel RNAscope. Authors show an increase in somatostatin (SST) CINs and a concomitant decrease in parvalbumin (PV) CINs. This appears to be mediated, at least in part, via *Mef2c* which can specify PV INs. Moreover, while the maturing PV INs have not been well characterized by molecular markers, the authors provide evidence that in addition to *Mef2c*, *Elmo1* and *Igfbp4* are candidate markers for maturing PV INs of the hippocampus. Moreover, *Maf* cDKOs exhibit reduced CINs and increased HINs that express a HIN-specific marker *Pnoc*. This paper follows up a previous one from the same group exploring the roles of *Mafb* and *c-Maf* in cortical interneuron development in mice. The overall experimentation and analyses our excellent, and the impact appropriate. The use of the system to identify candidate genes enriched in immature PV+ cells (well before PV expression) is outstanding. The strengths of this manuscript are: 1) High quality scRNA-seq dataset of P0 neocortical neurons in presence absence of *Mafb*/*c-Maf;* 2) Sequencing results argue in favor of direct cell-autonomous role for both factors -- pyramidal neuron and CGE neuron expression profiles largely unchanged; 3) It gives valuable insight into some of the downstream factors that underlie phenotypes described previously; 4) Adds to other evidence that *Mef2c* is an early Pv cell marker; 5) Identifies *Pnoc* as a hippocampal interneuron marker.

Essential revisions:

1\) The main weakness is that it serves as something of a companion piece to their previous study, which takes away from much of its novelty. In fact, it is difficult to follow parts of this manuscript without having first read Pai et al., 2019 Cell Reports beforehand. Re-writing the text to reinforce the logical flow of the experiments and perhaps a schematic of the previous findings (something like Figure S2) along with what new has been identified would help the reader appreciate the work described.

2\) The use of muti-channel RNAscope to confirm scRNA-seq results needs some improvement. First, it would be helpful -- either in the main or in supplemental -- to show higher magnification images to clarify what is deemed double-positive. Second, some of the RNAscope images are less convincing, *Tcf12* and *Elmo 1* in particular. New, better images would be needed for these. Finally, Liu et al., 2019 and Tao et al., 2019 both describe the role of *Sp9* in PV cell migration to the cortex and describe dramatic phenotypes relating to the loss of PV cells in the cortex following *Sp9* conditional knockout in the MGE lineage. Given this well described role for *Sp9*, it is surprising that only a subset the tdTomato fate-mapped CINs are *Sp9* (\~22% of cortical cells even though PV should encompass \~50-60% of Nkx2-1 lineage) in Figure 3. The authors should address this apparent disparity in the Discussion.

3\) Please examine the morphology of SST and/or PV INs in vivo through neuron fills. The in vitro findings are compelling but would be greatly strengthened with by an in vivo analysis. This could also include the SST-cre Maf mutants which, at least the in vitro studies, suggest a role for Mafs in postmitotic INs.
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Author response

> Essential revisions:
>
> 1\) The main weakness is that it serves as something of a companion piece to their previous study, which takes away from much of its novelty. In fact, it is difficult to follow parts of this manuscript without having first read Pai et al., 2019 Cell Reports beforehand. Re-writing the text to reinforce the logical flow of the experiments and perhaps a schematic of the previous findings (something like Figure S2) along with what new has been identified would help the reader appreciate the work described.

We thank the reviewers for their inputs. In our initial submission, the editor suggested that we should reorganize the manuscript flow. We took the suggestion very seriously to reorganize the paragraphs and figures. These changes were presented in our previous formal submission. In response to the reviewers' comments, we now schematically summarized the findings from our previous *Cell Reports* paper (Pai et al., 2019) to help readers understand what was previously discovered and to help them understand the questions we address in the current paper. We hope these changes are helpful to the readers (Scheme 1-3 and Figure 3---figure supplement 1).

> 2\) The use of muti-channel RNAscope to confirm scRNA-seq results needs some improvement. First, it would be helpful -- either in the main or in supplemental -- to show higher magnification images to clarify what is deemed double-positive. Second, some of the RNAscope images are less convincing, Tcf12 and Elmo 1 in particular. New, better images would be needed for these. Finally, Liu et al., 2019 and Tao et al., 2019 both describe the role of Sp9 in PV cell migration to the cortex and describe dramatic phenotypes relating to the loss of PV cells in the cortex following Sp9 conditional knockout in the MGE lineage. Given this well described role for Sp9, it is surprising that only a subset the tdTomato fate-mapped CINs are Sp9 (\~22% of cortical cells even though PV should encompass \~50-60% of Nkx2-1 lineage) in Figure 3. The authors should address this apparent disparity in the Discussion.

We have extensively modified Figure 3 based on reviewers' suggestion. We separated the original Figure 3 to generate (1) a new Figure 3, which highlights the expression of *Mef2c*, *Sp9* and *Igfbp4* in lower and higher magnification; (2) a new Figure 3---figure supplement 2, which highlights the expression of *Tcf12*, *Elmo1* and *Arl4d* in lower and higher magnification; (3) a new Figure 3---figure supplement 3, which provides the higher magnification views of marker expression in the *tdTomato+/Sst-* and *tdTomato+/Sst+* population in HINs.

We agree with the reviewers that some of the RNAscope images are less convincing, *Tcf12* and *Elmo1* in particular. Therefore, we now present higher magnification pictures showing INs that are considered marker positive for each gene (*Igfbp4*, *Sp9*, *Mef2c*, *Tcf12*, *Elmo1* and *Arl4d*) in the neocortex and in the hippocampus (Figure 3, Figure 3---figure supplement 2 and 3). The analysis of the result was conducted at the higher magnification and was easily quantifiable (Figure 3 and Figure 3---figure supplement 2). Furthermore, due to the current shelter-in-place order in San Francisco, all research work has been halted, and our institute does not allow any new experiment to be conducted until further noticed. In addition, the scientist who performed this experiment, prepared the manuscript and drafted this response letter has to leave UCSF by May 25th. Taken together and given these uncertain times, we kindly ask to not have to repeat a new set of RNAscope for *Tcf12* and *Elmo1*.

We understand reviewers' concern regarding the *Sp9* quantification results. We now have dedicated one paragraph in the Discussion for this:

"Of note, here we report that \~22% of the *Nkx2.1-Cre* lineage CINs are *Sp9* positive at P2. To our knowledge, this is the first report to show *Sp9* expression in CINs in the *Nkx2.1-Cre* lineage. We agree that 22% may be an underestimate because of several reasons: (1) when we looked at the *Sp9* expression in the hippocampus, \~60% of the PV candidate INs are *Sp9* positive; (2) the robustness of the *Sp9* RNAscope probe seemed to be stronger in the hippocampus region; (3) the robustness and efficiency of the *Sp9* RNAscope probe is not as strong as the traditional DIG-labeled *Sp9* probe in the neocortex as reported by the Allen Brain Institute. Additionally, recent studies have emerged to study the role of *Sp9* in IN development (Liu et al., 2019; Tao et al., 2019). Liu et al. reported around 50% PV+ *Nkx2.1-Cre* lineage CIN loss in adulthood when comparing *Nkx2.1-Cre-*generated *Sp9* conditional heterozygous and homozygous (cHet and cKO) mutants. However, it may be questionable to conclude that 50% of the PV CINs are *Sp9+* due to the fact that *Sp9* deletion also leads to 50% total loss of *Nkx2.1-Cre* lineage CINs (Liu et al., 2019). While more studies are needed to validate the roles of these candidate PV IN marker genes in PV IN development and maturation, recent reports on *Sp9* and *Mef2c* have provided a genetic foundation for our discovery of early candidate PV IN markers (Liu et al., 2019; Mayer et al., 2018; Tao et al., 2019)."

> 3\) Please examine the morphology of SST and/or PV INs in vivo through neuron fills. The in vitro findings are compelling but would be greatly strengthened with by an in vivo analysis. This could also include the SST-cre Maf mutants which, at least the in vitro studies, suggest a role for Mafs in postmitotic INs.

Due to the shelter-in-place situation, we are not allowed to conduct any experiment. However, to try to investigate the in vivo and in vitro correlation on *Maf* cDKO IN morphology, we revisited the 2D images from our previous MGE transplantation assay and compiled a collection of WT and *Maf* cDKO IN (these INs developed in a WT environment in vivo). The data suggested that the *Maf* cDKO INs have less neurites, which is consistent with our in vitro finding.

In our previous submission, we did include the *Sst-IRES-Cre Maf* cDKO data (Figure 4---figure supplement 2) to support the hypothesis that *Maf* and *Mafb* are functioning postnatally to mediate the CIN morphogenesis.

In our 2019 *Cell Reports* paper, we did not conduct the in vivo IN reconstruction in adult WT and *Maf* cDKO to support the in vitro morphology finding, which is a drawback of the study. However, we provided several other pieces of evidence in the *Cell Reports* paper to support the close correlation between in vitro and in vivo finding of *Maf* mutants. For example, we discovered that *c-Maf (Maf)* cKO IN has increased excitatory input in vitro. With more *c-Maf (Maf)* cKO IN excitation, we observed decreased cortical excitability in acute brain slices using local field potential (LFP) recording. in vitro cultured *Maf* cDKO INs did not show alterations in excitatory synapse formation. In correspondence to that, we did not observe obvious changes in cortical excitability in the ex vivo LFP recording, We also dissected E13.5 MGE progenitors from the *Maf* cDKO and transplanted these cells into P0 neocortex and allowed them to grow in an in vivo WT environment for 30 days. These transplanted cells demonstrated preferential loss of PV INs as observed in vivo.

[^1]: These authors contributed equally to this work.
